Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

and Ozempic (semaglutide) for weight loss and type 2 diabetes, respectively, reached DKr73.5bn. Novo Nordisk stated that obesity sales were the main driver – up 65% compared to Q1 2024.

Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Predicting weight loss using self-reported, digitally collected, real-world data after initiation of ...

Khalid bin Abdulaziz Al-Falih and several officials, along with representatives from Novo Nordisk and Lifera. Semaglutide GLP-1 treatments are the global market-leading therapeutics for weight ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.